AAAAAA

   
Results: 1-10 |
Results: 10
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
Authors: Somlo, G Chow, W Hamasaki, V Leong, L Margolin, K Morgan, R Sniecinski, I Frankel, P Reardon, D Longmate, J Raschko, J Shibata, S O'Donnell, M Smith, E Tetef, M Forman, S Yen, Y Molina, A Doroshow, JH
Citation: G. Somlo et al., Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies, BIOL BLOOD, 7(5), 2001, pp. 284-293
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH
Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576
Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial
Authors: Lara, PN Gandara, DR Longmate, J Gumerlock, PH Martin, DHML Edelman, J Gandour-Edwards, R Mack, PC Israel, V Raschko, J Frankel, P Perez, EA Lenz, HJ Doroshow, JH
Citation: Pn. Lara et al., Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial, CANC CHEMOT, 48(1), 2001, pp. 22-28
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
Authors: Morgan, RJ Synold, T Carr, BI Doroshow, JH Womack, EP Shibata, S Somlo, G Raschko, J Leong, L McNamara, M Chow, W Tetef, M Margolin, K Akman, S Longmate, J
Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
Authors: Morgan, RJ Doroshow, JH Leong, L Schriber, J Shibata, S Forman, S Hamasaki, V Margolin, K Somlo, G Alvarnas, J McNamara, M Longmate, J Raschko, J Chow, W Vasilev, S McGonigle, K Yen, Y
Citation: Rj. Morgan et al., Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer, BONE MAR TR, 28(9), 2001, pp. 859-863
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation
Authors: Spitzer, TR Friedman, CJ Bushnell, W Frankel, SR Raschko, J
Citation: Tr. Spitzer et al., Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation, BONE MAR TR, 26(2), 2000, pp. 203-210
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up
Authors: Morgan, RJ Braly, P Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Najera, L Johnson, D Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up, GYNECOL ONC, 77(3), 2000, pp. 433-438
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial
Authors: Tetef, M Leong, L Ahn, C Akman, S Chow, W Margolin, K Morgan, RJ Raschko, J Shibata, S Somlo, G Doroshow, JH
Citation: M. Tetef et al., Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial, CANCER INV, 17(2), 1999, pp. 114-117
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up
Authors: Morgan, RJ Braly, P Cecchi, G Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Parker, P Stein, A Cho, J Smith, E Coluzzi, P Najera, L Johnson, D Womack, E Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
Authors: Somlo, G Sniecinski, I ter Veer, A Longmate, J Knutson, G Vuk-Pavlovic, S Bhatia, R Chow, W Leong, L Morgan, R Margolin, K Raschko, J Shibata, S Tetef, M Yen, Y Forman, S Jones, D Ashby, M Fyfe, G Hellmann, S Doroshow, JH
Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806
Risultati: 1-10 |